Manuel C. Aivado
Net Worth
Last updated:
What is Manuel C. Aivado net worth?
The estimated net worth of Dr. Manuel C. Aivado is at least $7,420,000 as of 6 Jun 2018. He has received compensation worth at least $7,420,000 in Aileron Therapeutics, Inc..
What is the salary of Manuel C. Aivado?
Dr. Manuel C. Aivado salary is $1,060,000 per year as Pres, Chief Executive Officer & Director in Aileron Therapeutics, Inc..
How old is Manuel C. Aivado?
Dr. Manuel C. Aivado is 55 years old, born in 1970.
What stocks does Manuel C. Aivado currently own?
As insider, Dr. Manuel C. Aivado owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Aileron Therapeutics, Inc. (ALRN) | Pres, Chief Executive Officer & Director | 1,000 | $0 | $0 |
What does Aileron Therapeutics, Inc. do?
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.
Manuel C. Aivado insider trading
Aileron Therapeutics key executives
Aileron Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Manuel C. Aivado (55) Pres, Chief Executive Officer & Director
- Dr. Vojislav Vukovic M.D., Ph.D. (58) Senior Vice President & Chief Medical Officer
- Mr. Richard J. Wanstall M.B.A. (56) SVice President, Chief Financial Officer & Treasurer